Mucopolysaccharidosis Treatment Market Share

APAC Market Forecast

Asia Pacific industry is anticipated to hold largest revenue share of 38% by 2037. Growing awareness campaigns and improved medical education have led to higher rates of MPS diagnoses in the APAC region. The resulting rise in patient identification has catalyzed the demand for effective treatment options. According to a report, efforts to increase disease awareness have resulted in a substantial increase in MPS diagnoses across various countries in the Asia Pacific region. For instance, MPS II (Hunter syndrome) cases diagnosed in China doubled over a five-year period.

North American Market Statistics

The mucopolysaccharidosis treatment market in the North America region is projected to hold the second largest share during the forecast period. North America's advanced healthcare infrastructure, including specialized treatment centers and expert medical professionals, contributes to improved MPS patient care, diagnosis, and access to innovative therapies. The Canadian Society for Mucopolysaccharide and Related Diseases (Canadian MPS Society) highlights the establishment of specialized treatment centers and the growth of expertise in managing MPS cases across North America.